CAMBRIDGE, Mass.–(BUSINESS WIRE)–April 8, 2015–

Hydra Biosciences, a leader in the field of Transient Receptor Potential (TRP) channel modulation, today announced that Russell Herndon, President and CEO, will present a corporate update at Needham & Company’s 14th Annual Healthcare Conference. The presentation is Wednesday April 15, 2015, at 10:40 a.m. at the Westin Grand Central Hotel in New York City.

Needham & Company’s 14th Annual Healthcare Conference brings together institutional investors and venture capital firms with management teams from more than 100 biotechnology, specialty pharmaceutical, medical technology and diagnostic companies. The focus of this invitation only conference is to connect leading public and private life science companies with investors.

About Hydra Biosciences

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Mass. that develops drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. Hydra Biosciences’ proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com.

Corporate:
Hydra Biosciences
Russell Herndon, 617-494-5230 x3352
President and CEO
or
Media Contact:
LaVoieHealthScience
Kristina Coppola, 617-374-8800, Ext. 105
kcoppola@lavoiehealthscience.com

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.

Author
Topics